Freedom of Information Request: 0862 2020/21

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1^st April 2018.  Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

I am conducting some research into the treatment of Atopic Dermatitis in the UK, and how this compares with other countries in Europe.  I would really appreciate if you could answer two questions.

Queen Elizabeth Hospital Birmingham:

• First, could you tell me how many Atopic Dermatitis patients have been treated by your trust in the latest four months that you have data available for, and how many of these patients were paediatric versus adult?

1. 1. Adults: 20
   2. Paediatric: 1

• Second, for all Atopic Dermatitis patients (adult plus paediatric) treated by your trust in the latest four months, could you please provide the number of patients treated with each of the following:

High Potency topical steroids – 0

Ultraviolet light – 0 therapy                                                                                                

Azathioprine – 0

Ciclosporin – 0

Methotrexate – 1

Mycophenolate mefetil – 0

Acitretin – 0

Alitretinoin – 0

Dupilumab – 1

Upadacitinib – 0

Tacrolimus – 0

Pimecrolimus – 0

Heartlands, Good Hope and Solihull Hospitals:

• First, could you tell me how many Atopic Dermatitis patients have been treated by your trust in the latest four months that you have data available for, and how many of these patients were paediatric versus adult? Our systems do not record to this detail – we are unable to provide data by diagnosis.

• Second, for all Atopic Dermatitis patients (adult plus paediatric) treated by your trust in the latest four months, could you please provide the number of patients treated with each of the following: Our systems do not record to this detail – we are unable to provide data by diagnosis. The below figures are for all issues related to the Dermatology directorate.

High Potency topical steroids – 152

Ultraviolet light  therapy – this is not centrally recorded                                                                                         

Azathioprine – 16

Ciclosporin – 61

Methotrexate – 110

Mycophenolate mefetil – 25

Acitretin – 65

Alitretinoin – 1

Dupilumab – 56

Upadacitinib – 0

Tacrolimus – 14

Pimecrolimus – 7